Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 31;6(2):MMT20.
doi: 10.2217/mmt-2018-0010.

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma

Robert O Dillman  1   2   3 , Andrew N Cornforth  4 , Edward F McClay  5 , Carol Depriest  2
Affiliations
Review

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma

Robert O Dillman et al. Melanoma Manag. .

Abstract

Aim: Metastatic melanoma patients were treated with patient-specific vaccines consisting of autologous dendritic cells loaded with antigens from irradiated cells from short-term autologous tumor cell lines.

Patients & methods: A total of 72 patients were enrolled in a single-arm Phase I/II (NCT00948480) trial or a randomized Phase II (NCT00436930).

Results: Toxicity was minimal. Median overall survival (OS) was 49.4 months; 5-year OS 46%. A 5-year OS was 72% for 18 recurrent stage 3 without measurable disease when treated and 53% for 30 stage 4 without measurable disease when treated. A total of 24 patients with measurable stage 4 when treated (median of four prior therapies) had an 18.5 months median OS and 46% 2-year OS.

Conclusion: This dendritic cell vaccine was associated with encouraging survival in all three clinical subsets. Clinicaltrial.gov NCT00436930 and NCT00948480.

Keywords: autologous tumor antigens; dendritic cells; melanoma; patient-specific therapy; therapeutic vaccine.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure Manufacturing of vaccines and the conduct and monitoring of the clinical trials was financed by the Hoag Hospital Foundation and Hoag Hospital. This included financial support of the Hoag Cell Biology Laboratory, the clinical trials staff and RO Dillman. The recent analysis and preparation of this manuscript was supported by AIVITA Biomedical, Inc. RO Dillman is now the Chief Medical Officer for AIVITA Biomedical, Inc., and is an employee and has equity in that company. AN Cornforth is an employee and has equity in TCRR Therapeutics, Inc. RO Dillman was previously the holder of the INDs, and author and principle investigator for both clinical trials, which were conducted while he was medical director of the Hoag Cancer Center in Newport Beach, CA, USA. AN Cornforth was a scientist in the Hoag Cell Biology Laboratory until the fall of 2011. EF McClay and C Depriest have nothing to disclose. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Overall survival for all 72 melanoma patients treated with autologous dendritic cell vaccines loaded with autologous tumor antigens and survival in a single arm Phase II trial (n = 54) and in a randomized Phase II trial (n = 18).
Figure 2.
Figure 2.. Overall survival for melanoma patients treated with autologous dendritic cell vaccines loaded with autologous tumor antigens whose stages of disease at the time of treatment were stage 3 (n = 18), stage 4 with nonmeasurable disease per RECIST (n = 30), or measurable (M) disease per RECIST (n = 24).
M: Measurable; NM: Not measurable.
See this image and copyright information in PMC

References

    1. Atkins MB, Lotze MT, Dutcher JP. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105–2116 (1999). - PubMed
    1. Kirkwood JM, Manola J, Ibrahim JG. et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670–1677 (2004). - PubMed
    1. Dillman RO. Melanoma vaccines: trials and tribulations. Vaccine Dev. Ther. 3, 57–78 (2013).
    1. Morton DL, Mozzillo N, Thompson JF. et al. An international, randomized, Phase III trial of bacillus–Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J. Clin. Oncol. 25(Suppl. 18), 8508 (2007).
    1. Hodi FS, O’Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010). - PMC - PubMed

Associated data

LinkOut - more resources